Tags: Drug.

JNJ-26489112 is an anticonvulsant drug being developed by Johnson & Johnson for the treatment of epilepsy. JNJ-26489112 was designed as a successor to topiramate. It is expected to have fewer side effects than topiramate because it lacks activity against carbonic anhydrase.JNJ-26489112 is also being studied as a treatment for major depressive disorder.

JNJ-26489112_structural_formula.png
IUPAC name
(S)-N-[(6-Chloro-23-dihydrobenzo[14]dioxin-2-yl)methyl]sulfamide
PubChem
11616111

Loading...

This page contains content from the copyrighted Wikipedia article "JNJ-26489112"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.